Novartis started a review of the business in October 2021, after Sandoz had been suffering from pressure on sales and operating profits for several years due mainly to pricing pressures ...

Novartis has another phase 3 trial win in its ... with potentially serious side effects. In 2021, Calliditas Therapeutics’ corticosteroid-based Tarpeyo (budesonide) became the first FDA-approved ...

Positioning itself as a pure-play innovative medicines company, Novartis is bullish about the growth towards 2030 by placing an emphasis on a streamlined portfolio to drive sales, says CEO Vas ...

the DeepMind spin-off launched in 2021 by Demis Hassabis, coinventor of the protein-folding software AlphaFold and a winner of the 2024 Nobel Prize in Chemistry. Now, Marshall says, Novartis’s ...

WASHINGTON, Jan 15 - A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' (NOVN.S), opens new tab blockbuster heart-failure drug ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...